NCT03175523终止不适用
HOW To Optimally Implant BioResorbable Scaffold - Intravascular Imaging Versus Quantitative Coronary Angiography Guidance
Seung-Jung Park1 个研究点 分布在 1 个国家目标入组 84 人开始时间: 2017年9月29日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 84
- 试验地点
- 1
- 主要终点
- Target lesion failure
研究概览
简要总结
The objective of this trial is to compare clinical outcomes between imaging-guided and QCA-guided strategy in patients with native coronary artery disease undergoing BRS implantation.
详细描述
The investigators hypothesized that intravascular imaging-guided BRS implantation is superior to QCA-guided BRS implantation with respect to target lesion failure in patients with native coronary artery disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women at least 19 years of age
- •Typical chest pain or objective evidence of myocardial ischemia suitable for elective percutaneous coronary intervention
- •Native coronary artery lesions with lesion length 50mm and less and reference vessel diameter of 2.5 ~ 3.75mm by quantitative coronary angiography assessment
- •The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.
排除标准
- •Angiographic exclusion criteria: any of the followings
- •Small vessel: mean reference size < 2.5 mm by quantitative coronary angiography
- •True bifurcation lesion with a large side branch (reference vessel diameter > 2.3mm) requiring a complex two-stent approach
- •Left main lesions
- •Ostial lesions within 3mm of the origin: right coronary artery, left anterior descending, or left circumflex artery
- •Impaired delivery of the Absorb bio- resorbable vascular scaffold is expected:
- •Extreme angulation (≥90°) proximal to or within the target lesion.
- •Excessive tortuosity (≥two 45° angles) proximal to or within the target lesion.
- •Moderate or heavy calcification proximal to or within the target lesion.
- •In-stent restenotic lesions
- •ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (with 12- 24 hour after symptoms onset)
- •Prior percutaneous coronary intervention within the target vessel during the last 12 months.
- •Prior percutaneous coronary intervention within the non-target vessel or any peripheral intervention is acceptable if performed anytime >30 days before the index procedure, or between 24 hours and 30 days before the index procedure if successful and uncomplicated.
- •Left ventricular ejection fraction (LVEF) < 30%
- •Hypersensitivity or contraindication to device material and its degradants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be adequately pre-medicated.
- •Persistent thrombocytopenia (platelet count <100,000/µl)
- •Any history of hemorrhagic stroke or intracranial hemorrhage, transient ischemic attack or ischemic stroke within the past 6 months
- •A known intolerance to a study drug (aspirin, clopidogrel or ticagrelor)
- •Patients requiring long-term oral anticoagulants or cilostazol
- •Any surgery requiring general anesthesia or discontinuation of aspirin and/or an Adenosine diphosphate(ADP) antagonist is planned within 12 months after the procedure.
- •A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer.
- •Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.
- •Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (alanine transaminase (ALT) or aspartate transaminase (AST) > 3 times upper limit of normal).
- •Life expectancy < 5 years for any non-cardiac or cardiac causes
- •Unwillingness or inability to comply with the procedures described in this protocol.
- •Patient's pregnant or breast-feeding or child-bearing potential.
结局指标
主要结局
Target lesion failure
时间窗: 1 year
the cumulative incidence of cardiac death, target vessel myocardial infarction or ischemia-driven target lesion revascularization at 12 months after the index procedure.
次要结局
- Procedural success(24 hours after an index procedure)
- Myocardial infarction(1 year, and 5 years)
- Target lesion revascularization(1 year, and 5 years)
- In-scaffold restenosis on coronary CT angiography(1 year, and 5 years)
- Target lesion failure (TLR)(1 year, and 5 years)
- A composite event(1 year, and 5 years)
- Stroke(1 year, and 5 years)
- Any revascularization(1 year, and 5 years)
- Device success(1 hour after an index procedure)
- Death(1 year, and 5 years)
- Scaffold thrombosis(1 year, and 5 years)
研究者
Seung-Jung Park
Professor
Asan Medical Center
研究点 (1)
Loading locations...
相似试验
终止
不适用
HOW To Optimally Implant BioResorbable Scaffold - Intravascular Imaging versus Quantative Coronary Angiography guidanceDiseases of the circulatory systemKCT0002921Asan Medical Center800
终止
不适用
Comparison of the Efficacy of a Biological Implant to Reinforce Overlapping Sphincter Repair Versus Overlapping Sphincter Repair AloneAnal IncontinenceFecal IncontinenceNCT01044589Massarat Zutshi13
招募中
不适用
Two-unit Cantilever Implant Prostheses Made of Monolithic Zirconia or PFMJaw, Edentulous, PartiallyMissing TeethNCT04713800University of Geneva, Switzerland38
已完成
不适用
Comparison of the accuracy of guided and conventional surgery for implant placementEdentulous arcadeC05.500.480RBR-8556fzpniversidade Paulista
已完成
不适用
Prospective Evaluation of a Surgical Solution for Breast Cancer-Associated LymphedemaLymphedemaEdemaNCT02734979Stanford University1